The Results of Phase I Pharmacokinetic Similarity Study of Boan Biotech’s Nivolumab Published in Journal of BioDrugsThe phase I clinical study aimed to establish the pharmacokinetic (PK) similar...
YANTAI, China, Aug. 27, 2024-- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 363 millio...
Boan Biotech today announced that it has received the U.S. FDA clearance for clinical trials of its dulaglutide injection (BA5101). BA5101 is a proposed biosimilar to Trulicity® intended for glycemic ...